Saturday 17 October 2026
Export SVRA’s income statement to Excel — free account
Savara Inc.
SVRA Healthcare Biotechnology
In the quarter to June 2026, EPS fell 14.3%, free cash flow fell 14.1% and total debt rose 1.54%, each against the same quarter a year earlier.
4.45
0.29
−6.12%
Follow SVRA
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (105.48%) | (79.95%) | (63.45%) | (78.74%) |
+8 more TTM periods Free account |
|
| (78.28%) | (63.01%) | (50.97%) | (60.91%) | ||
ROIC |
(12,213.18%) | (2,513.91%) | 0.00% | 0.00% | |
Return on Tangible Assets |
(86.33%) | (66.79%) | (53.69%) | (103.69%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(0.44) | (0.42) | (0.45) | (0.46) | |
Free Cash Flow |
(110.66) | (106.97) | (101.06) | (99.27) | |
Capital Expenditures |
(0.28) | (0.07) | (0.02) | (0.01) | |
| Other line items | |||||
Cash ROIC |
(31.91%) | (26.16%) | (21.56%) | (39.94%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.79 | 0.83 | 0.85 | 0.86 | |
Depreciation/Fixed assets |
(1.84) | (11.51) | (21.68) | (37.24) | |
Capex/Depreciation |
0.24 | 0.05 | 0.01 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.44) | (0.42) | (0.45) | (0.46) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates